MedTrace Logo

Dyslipidemia in Cardiovascular Disease

NCT01029522 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 244

Last updated 2012-08-09

No results posted yet for this study

Summary

A multi-center, randomized, double-blinded equivalence clinical trial to evaluate efficacy and safety of LipiLou 20 mg versus Lipitor 20 mg in hypercholesterolemic patients with higher risk cardiovascular disease in Korea.

Conditions

Interventions

DRUG

Atorvastatin (Lipilou)

treatment of dyslipidemia administration : PO, qod

DRUG

Atorvastatin (Lipitor)

treatment of dyslipidemia administration : PO, qod

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • KIM hyo soo, ph D · yongon-dong, jong-ro gu, Seoul National University Hospital, South of Korea

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2008-10-31
Completion
2009-11-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01029522 on ClinicalTrials.gov